Browsing Tag
AbbVie
66 posts
Aldeyra Therapeutics brings biotech CFO experience to board amid ALDX regulatory reset
Find out how Aldeyra Therapeutics’ new board appointment could shape ALDX stock sentiment, FDA strategy and reproxalap’s next chapter for investors now.
Pharma M&A trends 2026: Why $1.3tn in firepower is meeting the steepest patent cliff in industry history
Big pharma has $1.3 trillion to deploy and $230 billion in revenue going off-patent by 2030. The 2026 deal map shows where the panic is real.
Viatris and the presbyopia drug race: What ASCRS 2026 data means for the MR-141 FDA decision in October
Viatris presents full VEGA-3 Phase 3 data for MR-141 presbyopia drop at ASCRS 2026. FDA PDUFA date is October 17, 2026. Market context, competitive landscape, and investor outlook.
Lundbeck’s Vyepti shows real-world migraine relief in patients failed by prior CGRP treatments
New INFUSE study data shows Vyepti may improve outcomes in migraine patients unresponsive to CGRP therapies. Find out what this means for the market.
Emmecell names ex-AbbVie executive Ramin Valian as CEO to lead cell therapy platform
Emmecell names Ramin Valian as CEO to guide its magnetic cell delivery platform toward pivotal trials. Find out what this leadership shift means for the industry.
Emmecell taps AbbVie veteran Ramin Valian as CEO to lead magnetic cell therapy into pivotal trials
Emmecell has named former AbbVie executive Ramin Valian as CEO to lead its magnetic cell therapy platform into pivotal trials. Find out what this signals next.
AbbVie strengthens U.S. manufacturing strategy with Arizona facility deal, reinforcing long-term supply resilience
Find out how AbbVie’s Arizona manufacturing acquisition strengthens U.S. drug production and reinforces long-term supply resilience.
FDA authorizes breakthrough Epkinly regimen from AbbVie for relapsed or refractory follicular lymphoma
Discover how AbbVie’s newly approved Epkinly regimen with rituximab and lenalidomide is redefining treatment for relapsed or refractory follicular lymphoma.
Breakthrough REZOLVE-AD results position Rezpegaldesleukin as a potential first-in-class IL-2 Treg therapy for atopic dermatitis and asthma
Rezpegaldesleukin delivers strong dual skin and asthma results in the REZOLVE-AD study — find out how Nektar Therapeutics plans to advance its IL-2 Treg platform in 2026.
Are short-acting psychedelics the next big bet in mental health? What pharma’s billion-dollar moves suggest
Are short-acting psychedelics the future of psychiatry? Pharma’s billion-dollar bets say yes. We explore what’s behind the new wave of scalable mental health drugs.